Possibilities of some probiotic strains in the eradication of Helicobacter pylori in vitro and in vivo

  • Authors: Suvorov A.N1, Baryshnikova N.V1,2, Svarval A.V3, Nijazov R.M4
  • Affiliations:
    1. First St. Petersburg State Medical University n.a. acad. I.P. Pavlov of RMH
    2. Institute of Experimental Medicine
    3. St. Petersburg Scientific Research Institute of Epidemiology and Microbiology. n.a.Pasteur
    4. Clinical Hospital FGHI Occupational Health Facility of the Ministry of Internal Affairs of the Russian Federation for the St. Petersburg and Leningrad Region
  • Issue: No 2 (2018)
  • Pages: 74-78
  • Section: Articles
  • URL: https://journals.eco-vector.com/2073-4034/article/view/294586
  • ID: 294586

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Purpose: to evaluate the antihelicobacter action of some probiotics in vitro and in vivo. Material and Methods. 3 probiotics were used: 1st - Enterococcus faecium strain L-3, 2nd - Bacillus subtilis, 3rd - combination of Bifidobacterium longum and Enterococcus faecium. In vitro, the growth of 14 strains of H. pylori against the background of the addition of probiotics was evaluated. Probiotic probes were diluted in distilled water in a ratio of 1:100 and then added to an agar plate, on which the H. pylori strain was plated. Analysis for growth was carried out on the 6-7th day. Fifty-five patients with H. pylori-associated chronic gastritis were divided into 3 groups: 1st group received B. subtilis; 2nd - E. faecium, 3rd - standard triple eradication therapy (omeprazole, amoxicillin, clarithromycin for 7 days). Results. Inhibition of H. pylori growth occurred in 50% of cases on contact with a B. subtilis-based probiotics, in 78.6% of cases on contact with Enterococcus faecium strain L-3, and in 64% of cases on contact with a combination of B. longum and E. faecium. Eradication efficacy (in vivo) was 39%, 41 and 60% in the 1st, 2nd and 3rd groups, respectively. Conclusions. The results obtained can be explained by the direct antagonistic action of probiotics against H. pylori, possibly due to the production of bacteriocins. This hypothesis needs further in-depth study.

Full Text

Restricted Access

About the authors

A. N Suvorov

First St. Petersburg State Medical University n.a. acad. I.P. Pavlov of RMH

N. V Baryshnikova

First St. Petersburg State Medical University n.a. acad. I.P. Pavlov of RMH; Institute of Experimental Medicine

Email: baryshnikova_nv@mail.ru
PhD

A. V Svarval

St. Petersburg Scientific Research Institute of Epidemiology and Microbiology. n.a.Pasteur

R. M Nijazov

Clinical Hospital FGHI Occupational Health Facility of the Ministry of Internal Affairs of the Russian Federation for the St. Petersburg and Leningrad Region

References

  1. Ткаченко Е.И., Авалуева Е.Б., Успенский Ю.П., Волков М.Ю., Сказываева Е.В., Можелис Ю.В., Захарченко М.М. Эрадикационная терапия, включающая пробиотики: консенсус эффективности и безопасности. Клиническое питание. 2005;1:14-20.
  2. Суворов А.Н., Симаненков В.И. H. pylori как возбудитель заболеваний желудочно-кишечного тракта. Генетика патогенности. Возможность эрадикации с использованием пробиотиков (лекции для врачей). СПб., 2006. 12 с.
  3. Gotteland M., Brunser O., Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Alimentary Pharmacology and Therapeutics. 2006;23(8):1077-86.
  4. Суворов А.Н.? Алехина Г.Г. Драже «Ламинолакт» - эффективное средство для нормализации микробиоценоза кишечника. Гастробюллетень. 2001;1:24.
  5. Барышникова Н.В. Эффективность пробиотической терапии в коррекции нарушений микробиоценоза кишечника у больных хроническим гастродуоденитом, ассоциированным с Helicobacter pylori. Вестник СПб., 2006;2:89-92.
  6. Caramia G. Probiotics from Mechnicoff to the current preventive and therapeutics possibilities. La Pediatria medica e chirurgica: Medical and Surgical Pediatrics. 2004;26(1):19-33.
  7. Limdi J.K., O'neill C., McLaughlin J. Do probiotics have a therapeutic role in gastroenterology? World J. Gastroenterol. 2006;12(34):5447-57.
  8. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment. Pharmacol. Ther. 2010;32:1069-79.
  9. Malfertheiner P., Megraud F., O'Morain C.A., Atherton J., Axon A.T., Bazzoli F., Gensini G.F., Gisbert J.P., Graham D.Y., Rokkas T., El-Omar E.M., Kuipers E.J. European Helicobacter Study Group Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut. 2012;61:646-64.
  10. Malfertheiner P., Megraud F., O'Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., Bazzoli F., Gasbarrini A., Atherton J., Graham D.Y, Hunt R., Moayyedi P., Rokkas T., Rugge M., Selgrad M., Suerbaum S., Sugano K., El-Omar E.M. et al. Management of Helicobacter pylori infection -the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30.
  11. Ткаченко Е.И., Успенский Ю.П., Барышникова Н.В. Оптимизация лечения заболеваний, ассоциированных с Helicobacter pylori. Врач. 2012;1:36-8.
  12. Rustamov M.N., Lazebnik L.B. Use of probiotics in the treatment of patients with Helicobacter pylori-positive duodenal ulcer. Научно-практические аспекты кардиологии и внутренних болезней. Минск, 2013. С. 298-301.
  13. Rustamov M.N., Lazebnik L.B. Effect of nonpharmacologic factors in treatment of patients with Helicobacter pylori - associated duodenal ulcer. Central Asia Gastroenterology Week-2013. Consilium. 2013. 84 р.
  14. Козлова Д.И. Состояние кишечного микробиоценоза и течение H. pylori-ассоциированного гастрита в условиях эрадикационной и синбиотической терапии. Дисс. канд. мед. наук. СПб., 2004.
  15. Барышникова Н.В. Монотерапия пробиотиками как альтернатива стандартной эрадикационной терапии больных Helicobacter pylori-ассоциированными заболеваниями. Сборник научных материалов V конгресса «Рациональная фармакотерапия и клиническая фармакология». СПб., 2010. С. 27-32.
  16. Canducci F., Cremonini F., Armuzzi A. Probiotics and Helicobacter pylori eradication // Digestive and Liver Diseases: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2002;34(Suppl. 2):81-3.
  17. Plewinska E.M., Bak-Romaniszynh L., Czkwianianc E., Planeta-Malecka I. Bifidogenic properties of the probiotic bacteria in eradication Helicobacter pylori infection in children / Abstracts of World congress of gastroenterology. Montréal, Canada. 2005.
  18. Vandenplas Y., Czerucha D,, Surawicz C. Diarrhea: Treatment and prevention. Where do probiotics fit? Abstracts of World congress of gastroenterology. Montréal, Canada. 2005.
  19. Успенский Ю.П., Барышникова Н.В., Фоминых Ю.А. Лечение инфекции Helicobacter pylori: проблемы и перспективы. Consilium Medicum. Гастроэнтерология. (Прил.). 2015;1:8-17.
  20. Успенский Ю.П., Фоминых Ю.А., Иванов С.В., Менакер И.О. Эволюция в эрадикационной терапии НР-ассоциированных заболеваний. Выход за рамки стандартов? РМЖ. 2016;24(17):1144-52.
  21. Успенский Ю.П., Суворов А.Н., Барышникова Н.В. Инфекция Helicobacter pylori в клинической практике. СПб., 2011. С. 497-537.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies